CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alaunos Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alaunos Therapeutics Inc
2617 Bissonnet St, Suite 225
Phone: (617) 259-1970p:617 259-1970 HOUSTON, TX  77005  United States Ticker: TCRTTCRT

Business Summary
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. It is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. It is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board HolgerWeis 60 9/22/2023 12/15/2020
Interim Chief Executive Officer, Director Dale C.Hogue 54 1/20/2024 12/29/2023
Vice President - Finance FerdinandGroenewald 39 2/23/2024 2/23/2024
4 additional Officers and Directors records available in full report.

Business Names
Business Name
EASYWEB INC
EasyWeb Inc.
EasyWeb, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 34 (As of 2/15/2023)
Outstanding Shares: 16,041,804 (As of 2/1/2024)
Shareholders: 240
Stock Exchange: NASD
Federal Tax Id: 841475642
Fax Number: (617) 241-2855


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, March 27, 2024